Furthermore, in addition to the occurred resistance, EGFR TKIs are more associated with EGFR-activating mutations than wild-type EGFR (WT-EGFR), indicating that this strategy was of relatively little benefit to the majority of lung cancer patients with WT-EGFR. Here, EGFR is linked to lung cancer.